Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.58 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 4/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | SSTR2 | P30874 | 3/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3552603 | 0.91 | KCNH2 (0.60) | KCNH2SLC2A1MTORSSTR2PIM1 | |
| SCHEMBL3550302 | 0.91 | KCNH2 (0.60) | KCNH2SLC2A1MTORSSTR2PIM1 | |
| SCHEMBL3551596 | 0.91 | KCNH2 (0.60) | KCNH2SLC2A1MTORSSTR2PIM1 | |
| SCHEMBL2936905 | 0.84 | KCNH2 (0.59) | KCNH2SLC2A1 | |
| SCHEMBL3546002 | 0.83 | KCNH2 (0.47) | KCNH2MTORSSTR2PIM1 | |
| SCHEMBL3146445 | 0.82 | SLC2A1 (0.47) | KCNH2SLC2A1HTR1A | |
| SCHEMBL3224839 | 0.82 | SLC2A1 (0.47) | KCNH2SLC2A1HTR1A | |
| SCHEMBL3326906 | 0.82 | SLC2A1 (0.47) | KCNH2SLC2A1HTR1A | |
| SCHEMBL3548455 | 0.81 | KCNH2 (0.55) | KCNH2SLC2A1MTOR | |
| SCHEMBL3548451 | 0.81 | KCNH2 (0.55) | KCNH2SLC2A1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001887-B1 | PYRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2010-09-15 | — | — | EP | claimed |
| US-20090062265-A1 | Pyrrolo-Quinoxalinone Derivatives as Antibacterials | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | claimed |
| EP-2001887-B1 | PYRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2010-09-15 | — | — | EP | disclosed |
| US-7709483-B2 | Pyrrolo-quinoxalinone derivatives as antibacterials | GLAXO GROUP LIMITED (GB) | 2010-05-04 | — | — | US | disclosed |
| US-20090062265-A1 | Pyrrolo-Quinoxalinone Derivatives as Antibacterials | GLAXO GROUP LIMITED (GB) | 2009-03-05 | — | — | US | disclosed |
| EP-2001887-A1 | PYRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS | Glaxo Group Limited (GB) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007115947-A1 | PYRROLO-QUINOXALINONE DERIVATIVES AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062265-A1 | Pyrrolo-Quinoxalinone Derivatives as Antibacterials | NQO2, PPOX, ASNS | KCNH2 2502/4885SLC2A1 4506/4885MTOR 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.